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Abstract
Background: Buckwheat (BW) is the source of a life-threat-
ening allergen. Fag e 3-specific serum IgE (sIgE) is more use-
ful than BW-sIgE for diagnosis; however, it is unknown 
whether Fag e 3-sIgE can predict oral food challenge (OFC) 
results and anaphylaxis. This study aimed to clarify the effi-
cacy of Fag e 3-sIgE in predicting OFC results and anaphy-
laxis. Methods: We conducted a retrospective review of BW- 
and Fag e 3-sIgE data obtained using the ImmunoCAP® as-
say system and fluorescent enzyme-linked immunosorbent 
assay from children who underwent OFC using 3,072 mg of 
BW protein between July 2006 and March 2014 at Sagami-
hara National Hospital, Kanagawa, Japan. Results: We ana-
lyzed 60 patients aged 1.9–13.4 years (median 6.0 years); 20 
(33%) showed objective symptoms upon BW OFC. The pa-
tients without symptoms had significantly lower Fag e 3-sIgE 
than those with non-anaphylactic (p < 0.001) and anaphylac-
tic reactions to BW (p = 0.004). Fag e 3-sIgE was the only test-
ed factor that significantly predicted positive OFC results 
(odds ratio 8.93, 95% confidence interval 3.10–25.73, p < 
0.001) and OFC-induced anaphylaxis (2.67, 1.12–6.35, p = 
0.027). We suggest that a threshold Fag e 3-sIgE level of 18.0 
kUE/L has 95% probability of provoking a positive reaction to 
BW. Conclusions: Fag e 3-sIgE predicted OFC results and 
OFC-induced anaphylaxis. We further emphasize paying 
careful attention to the risk of BW OFC-induced anaphylaxis.
© 2018 S. Karger AG, Basel 
Published by S. Karger AG, Basel
Introduction
Buckwheat (BW) has been widely consumed in Asian 
countries and is increasing in popularity in the USA and 
Europe [1, 2]. However, it can be a potent source of aller-
gens and can cause life-threatening anaphylaxis. In Japan, 
BW is the fourth-most common cause of food-induced 
anaphylaxis [3–5]. The estimated prevalence of BW al-
lergy in school-children in Japan is 0.22% [6]. More than 
Edited by: R. van Ree, Amsterdam.
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half of challenge-positive patients for BW present ana-
phylaxis [4]. BW serum-specific IgE (sIgE) levels have 
been useful for diagnosing BW allergy [4]; however, Fag 
e 3 (7S globulin, vicilin fragment) is a novel candidate as 
a more useful BW allergen component for diagnosis [7] 
than BW alone. Currently, the most accurate diagnosis 
method for BW allergy is oral food challenge (OFC). Our 
study aimed to clarify the efficacy of Fag e 3-sIgE to pre-
dict OFC results.
Materials and Methods
Study Population and Enrollment
We retrospectively analyzed data from children who under-
went an OFC with BW in Sagamihara National Hospital, Kanaga-
wa, Japan, between July 2006 and April 2014. About 60% of pa-
tients were referred from primary care clinics, and the rest were 
admitted directly without referral. Patients who were allergic or 
suspected to be allergic to BW were diagnosed based on the pres-
ence of a history of immediate reaction to BW or past or current 
atopic dermatitis with positive BW-sIgE. We enrolled only those 
undergoing their first BW OFC and did not have missing clinical 
or laboratory data. 
Oral Food Challenge
In total, 64 g of BW noodles containing 3,072 mg of BW protein 
were used for OFC as previously described [4] (based on the 2017 
Japanese Pediatric Guidelines for Food Allergy [8]). Treatments 
for provoked reaction were based on the European Academy of 
Allergy and Clinical Immunology’s food allergy and anaphylaxis 
guidelines [9]. Anaphylaxis was defined according to World Al-
lergy Organization Anaphylaxis Guidelines [10], and severity of 
symptoms was defined according to Japanese anaphylaxis guide-
lines [8, 11]. 
Laboratory Data
We assessed BW-sIgE within 180 days of the OFC using the 
ImmunoCAP® assay system (Thermo Fisher Scientific/Phadia, 
Uppsala, Sweden). Fag e 3-sIgE was analyzed using stored serum 
samples via a fluorescent enzyme-linked immunosorbent assay 
(ELISA) at Kyoto University using previously described methods 
[7]. The serum sample was stored at –80  ° C for a median of 2.5 
years (range 0.5−8.2 years) before analysis. These stored condi-
tions did not affect the stability of sIgE [12–14].
Statistical Analysis
We expressed data as median values and ranges, used the 
Mann-Whitney U or the Fisher exact test for statistical compari-
sons, as appropriate, and considered p values of < 0.05 as statisti-
cally significant. We performed univariate and multivariate analy-
ses using logistic regression. To create probability curves, we used 
regression analysis after logarithmic transformation of sIgE values, 
as previously published [15]. We used SPSS v24.0 (IBM Corp., Ar-
monk, NY, USA) to perform all statistical analyses. 
Ethical Considerations
In accordance with the Declaration of Helsinki, the study de-
sign and risks of anaphylaxis during the OFC were fully explained 
to patients and their guardians, both orally and in writing, and 
written informed consent was obtained from all participants for 
the OFC and publication of the data. All patient data were anony-
mized prior to analysis. We obtained approval from the institu-
tional review board of Sagamihara National Hospital. 
Results
Patient Background
In total, 362 patients underwent an OFC (Fig. 1). We 
excluded 295 patients owing to insufficient serum sam-
Excluded due to: 
missing clinical information (n = 3)
missing laboratory data (n = 4)
Underwent BW OFC with sufficient
Fag e 3 data (n = 67)
Underwent BW OFC
(n = 362)
Excluded due to insufficient serum
remaining sample for
Fag e 3 data (n = 295)
Included in the analysis
(n = 60)
Fig. 1. Study participation.
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ples for sIgE tests, 3 owing to a lack of clinical informa-
tion, and 4 owing to missing laboratory data. The remain-
ing 60 patients with suspected or definitive BW allergies 
were 1.9–13.4 years of age (median 6.0 years; Table 1), 10 
of whom had a history of reactions to BW, and 1 with a 
history of anaphylaxis due to BW. Median BW- and Fag 
e 3-sIgE levels were 2.8 kUA/L (range 0.15−25.9) and 0.14 
kUE/L (range 0.06−42.0), respectively. 
OFC Results
Twenty patients (33%) reacted, all with objective 
symptoms. Skin reactions were most common (15 
[75%]), followed by respiratory (12 [60%]), gastrointes-
tinal (11 [55%]), neurological (2 [10%]), and cardiovas-
cular (1 [5%]) symptoms. We observed anaphylactic re-
actions in 7 patients (35%). Moderate and severe symp-
toms, as defined in Japanese Guidelines for Food Allergy 
[8], were present in 9 (45%) and 5 patients (25%), respec-
tively. 
Fourteen patients (70%) received treatment. Oral an-
tihistamine was the most frequent treatment, adminis-
Table 1. Clinical and demographic characteristics of patients







Male sex 30 (75.0) 9 (69.2) 4 (57.1) 0.545
Age, years 5.9 (1.9–13.4) 7.4 (3.2–12.3) 7.4 (2.7–10.6) 0.259
A history of
An immediate reaction to BW 4 (10.0) 3 (23.1) 3 (42.9) 0.070
Anaphylaxis to BW 0 (0.0) 1 (7.7%) 0 (0.0) 0.333
Atopic dermatitis, current 18 (45.0) 5 (38.5) 4 (57.1) >0.999
Bronchial asthma, current 8 (20.0) 5 (38.5) 1 (14.3) 0.519
BW-sIgE, kUA/L 2.8 (0.76–25.9) 3.8 (0.4–15.2) 2.7 (0.15–12.6) 0.913
Fag e 3-sIgE, kUE/L 0.09 (0.06–8.3) 4.1 (0.09–23.2) 4.3 (0.09–42.0) <0.001
Total IgE, IU/mL 1,205 (2–17,100) 842 (113–9,510) 745 (26–1,930) 0.052
Values are expressed as n (%) or median (range). BW, buckwheat; sIgE, specific immunoglobulin E.
a Represents the statistical significance between negative cases and reactive cases. No significant difference among the 3 groups (no 
symptoms, non-anaphylactic, and anaphylactic) was seen without Fag e 3 sIgE (p < 0.001). 
Table 2. Diagnostic performance of BW- and Fag e 3-sIgE
BW-sIgE Fag e 3-sIgE
AUC 0.509 0.893
95% CI 0.348–0.669 0.808–0.977
Optimal cut-off value, kUE/L 3.8 0.3
Sensitivity, % 50.0 80.0
Specificity, % 65.0 87.3
AUC, area under the curve; BW, buckwheat; CI, confidence 

















Fig. 2. ROC curve analysis to diagnose buckwheat allergy. BW, 
buckwheat; ROC, receiver-operating characteristic; sIgE, specific 
IgE.
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tered in 13 patients (65%). β2 stimulant inhalation was 
administered to 11 patients (55%), intravenous steroids 
to 6 (30%), and intramuscular adrenaline injections to 2 
(10%). Of 7 patients who showed anaphylaxis, 5 did not 
need adrenaline injections because of a rapid improve-
ment in the respiratory symptoms following β2 stimulant 
inhalation (n = 4), or improvement in moderate skin 
symptoms and repeated vomiting after the administra-
tion of intravenous antihistamines and steroids.
Diagnostic Performance of BW and Fag e 3-sIgE 
The diagnostic performance of BW- and Fag e 3-sIgE 
was compared by calculating their respective area under 
the curve (AUC) and optimal cut-off values. The AUC for 
BW and Fag e 3-sIgE was 0.509 and 0.893, respectively 
(Fig.  2; Table 2). The optimal cut-off values were 3.8 
kUA/L and 0.3 kUE/L, respectively.
Risk Factors for Positive Challenge
Patients with positive OFC results more frequently 
had higher Fag e 3-sIgE (10-fold increments; odds ratio 
[OR] 8.93, 95% confidence interval [CI] 3.10–25.73, p < 
0.001) (Table 3). There was no significant difference be-
tween BW-sIgE and positive OFC results. There was also 
no significant difference between a history of an immedi-
ate reaction to BW and positive OFC. In a multivariate 
analysis adjusted for the presence of immediate reactions 
[4], Fag e 3-sIgE (10-fold increments, adjusted OR 8.93, 
95% CI 2.93–27.27, p < 0.001) remained a significant fac-
tor for positive OFC results. In a univariate analysis, Fag 
e 3-sIgE was the only significant factor for OFC-induced 
anaphylaxis (10-fold increments, OR 2.67, 95% CI 1.12–
6.35, p = 0.027) (Table 4), although this was nonsignifi-
cant in the multivariate analysis adjusted for immediate 
reaction.
Fag e 3-sIgE and Symptoms during OFC
Patients without symptoms had significantly lower 
Fag e 3-sIgE than those with non-anaphylactic (p < 0.001) 
or anaphylactic symptoms to BW (p = 0.004) (Fig.  3). 
Among challenge-positive patients (n = 20), those with 
gastrointestinal symptoms had higher Fag e 3-sIgE levels 
than those without such symptoms (p = 0.038). Although 
similar trends were observed for skin reactions and ana-
phylaxis with the Fag e 3-sIgE concentration, these were 
not statistically significant.
Table 3. Univariate and multivariate analyses of factors related to positive OFC results




p value Adjusted ORa
(95% CI)
p value
BW-sIgE (10-fold increments) 0.800 (0.223–2.878) 0.733 1.026 (0.269–3.924) 0.970
Fag e 3-sIgE (10-fold increments) 8.930 (3.099–25.729) <0.001 8.933 (2.927–27.265) <0.001
History of an immediate reaction to BW 3.857 (0.944–15.763) 0.060 –
BW, buckwheat; sIgE, specific immunoglobulin E; CI, confidence interval; OFC, oral food challenge; OR, odds 
ratio.
a Adjusted according to a history of an immediate reaction to BW.
Table 4. Univariate and multivariate analyses of factors related to OFC-induced anaphylaxis
Risk factors for OFC-induced
anaphylaxis (n = 60)
Crude OR
(95% CI)
p value Adjusted ORa
(95% CI)
p value
BW-sIgE (10-fold increments) 0.62 (0.096–4.02) 0.617 0.89 (0.13–6.09) 0.903
Fag e 3-sIgE (10-fold increments) 2.67 (1.12–6.35) 0.027 2.33 (0.96–5.66) 0.061
History of an immediate reaction to BW 4.93 (0.91–26.85) 0.065 –
 BW, buckwheat; sIgE, specific immunoglobulin E; CI, confidence interval; OFC, oral food challenge; OR, 
odds ratio.
a Adjusted according to a history of an immediate reaction to BW.
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Probability of Failed Challenge and Anaphylaxis 
during OFC
Figure 4 presents fitted predicted probability curves 
for positive challenge and OFC-induced anaphylaxis at a 
given Fag e 3-sIgE concentration. We suggest that a 
threshold Fag e 3-sIgE concentration of 18.0 kUE/L would 
have an approximately 95% probability of inducing any 
reaction to BW (Table 5). We were unable to calculate the 
sIgE concentration level at which approximately 95% of 
the patients are predicted to experience anaphylaxis (the 
95% predictive decision point). The 50% predictive deci-
sion point for Fag e 3-sIgE to anaphylaxis was 75.4 kUE/L. 
Discussion
This was the first study to calculate the 95% predictive 
decision point for Fag e 3-sIgE. Although the usefulness 
of Fag e 3-sIgE has been reported, these studies included 
patients with a convincing history [6], whereas we includ-
ed only OFC-proven BW-allergic and nonallergic pa-
tients. Consistent with a previous report [4], we observed 
frequent anaphylactic reactions and severe symptoms. 
Furthermore, we were able to estimate the risk of OFC-




























































































Fig. 3. Fag e 3-sIgE and symptoms during oral food challenge 
(OFC). a Fag e 3-sIgE among patients with no symptoms, non-
anaphylactic reactions, and anaphylactic reactions during OFC. 
b–d Fag e 3-sIgE among patients with no symptoms; patients 
showing symptoms other than skin, respiratory, and gastrointesti-
nal (GI) symptoms; and patients with skin, respiratory, and GI 
symptoms, respectively, during OFC. Median and interquartile 
range are indicated by horizontal lines.
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BW OFC may induce severe reactions [4]. Therefore, 
knowing the probability for a reaction and anaphylaxis 
may help assess the risk of a positive OFC result and OFC-
induced anaphylaxis prior to the challenge. Generally, 
many patients need BW OFC because BW-sIgE can only 
roughly predict OFC results. However, similar to a previ-
ous study [6], Fag e 3-sIgE was more useful than BW-sIgE 
for predicting positive reactions. It was also useful for 
predicting OFC results. This suggests that OFC with BW 
in patients with Fag e 3-sIgE > 18 kUE/L should be avoid-
ed. These results were derived using ELISA. Probability 
curves of different assays cannot be applied interchange-
ably [16]; therefore, it is unknown whether other methods 
would achieve 95% predictive decision points similar to 
those obtained for Fag e 3-sIgE.
In some foods, including those with minor allergens, 
95% predictive decision points were reported [17, 18]. 
Component-resolved diagnosis (CRD) improves the ac-
curacy of diagnosing IgE-mediated food allergy [19]. In 
some allergenic foods, like wheat and peanut, CRD (ω-5 
gliadin, Ara h 2) provided a more precise diagnostic per-
formance than crude food allergen-sIgE does, and only 
CRD showed 95% predictive decision points [20, 21]. Al-
though BW-sIgE is useful [4], the 95% predictive decision 
points were not calculated. Our study also revealed that 
Fag 3e 3, a component of BW, is more useful than crude 
BW.
There were some limitations to our study. First, the 
OFCs were not double-blinded, placebo-controlled chal-
lenges. However, all OFC-positive patients had objective 
symptoms, including anaphylaxis; therefore, this should 
not actually affect the conclusions. Second, we performed 
a skin prick test (SPT) for only a few patients; combining 
the SPT and Fag e 3-sIgE may improve diagnostic perfor-
mance. Moreover, we could not compare Fag e 3-sIgE and 
the SPT. Fag e 3-slgE is currently commercially unavail-
able, and the SPT test is cheaper and faster. Accordingly, 
there is a need for further study to compare the two. Cur-
rently, the commercial availability of Fag e 3-sIgE is lim-
ited; therefore, its use in clinical settings is also limited. 
Finally, there was a potential selection bias in our study. 
For example, patients with a strong history of anaphylax-
is might avoid OFC. We excluded many patients with 
missing Fag e 3-sIgE data and included only 60 with BW 
OFC, primarily because many patients had an insufficient 
residual serum sample. The differences in Fag e 3-sIgE 
concentrations between patients with and without gastro-
intestinal symptoms, but not between those with other 
symptoms and anaphylaxis, may have originated from the 
small sample size. Larger prospective studies are needed. 
In conclusion, Fag e 3-sIgE predicted OFC results and 
OFC-induced anaphylaxis. We further emphasize paying 
careful attention to the risk of BW OFC-induced anaphy-
laxis. 
Table 5. Clinical efficacy of Fag e 3-sIgE for predicting a positive oral food challenge to buckwheat
Probability 50% pred. probability 90% pred. probability 95% pred. probability
Fag e 3-sIgE, kUE/L 0.8 8.2 18.0 
95% CI 0.4 to 3.0 2.4 to 200.0 –4.3 to 871.0
CI, confidential interval; sIgE, specific immunoglobulin E; pred., predicted.
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Fig. 4. Probability curves representing positive outcomes of oral 
food challenge (OFC) and anaphylaxis during OFC at a given Fag 
e 3-sIgE in 60 patients. The solid line represents the probability of 
an objective reaction (n = 20). The dotted line represents the prob-
ability of an anaphylactic reaction (n = 7). 
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